Skip to main content
. 2017 Jan 11;8(4):383–392. doi: 10.1080/21655979.2016.1235101

Table 1.

Comparison of demographic, clinic and pathological characteristics of Her-2 positive and negative patients.

Variables HER-2 negative n = 99 HER-2 positive n = 159 P
Age(year), mean±sd. 50.06 ± 13 .77 49.23 ± 10 .45 1.000
Onset time, n (%)     0.134
 Pre-menopause 51(51.52) 97(61.01)  
 Post-menopause 48(48.48) 62(38.99)  
Tumor location, n (%)     0.430
 Left 43(43.43) 81(50.94)  
 Right 55(55.56) 77(48.43)  
 Bilateral 1(1.01) 1(0.63)  
First symptoms     0.550
 Lump 92(92.93) 152(95.60)  
 Nipple discharge 4(4.04) 4(2.52)  
 Axillary lump 2(2.02) 3(1.89)  
 Calcification 1(1.01) 0(0.00)  
Vessel carcinoma embolus, n (%)     0.126
 No 90(90.91) 134(84.28)  
 Yes 9(9.09) 25(15.72)  
Pathological type, n (%)     0.002
 IDC 75(76.53) 141(88.68)  
 Other 23(23.47) 18(11.32)  
Histological grade, n (%)     0.001
 1 14(14.14) 6(3.77)  
 2 57(57.58) 81(50.94)  
 3 28(28.28) 72(45.28)  
Diameter of lumps, n (%)     0.036
 T1 58(58.59) 67(42.14)  
 T2 37(37.37) 82(51.57)  
 T3 4(4.04) 10(6.29)  
axillary lymph node metastasis, n (%)     0.024
 N0 66(66.67) 78(49.06)  
 N1 20(20.20) 45(28.30)  
 N2 4(4.04) 19(11.95)  
 N3 9(9.09) 17(10.69)  
pTNM staging, n (%)     0.033
 0–I 42(42.42) 44(27.67)  
 II 45(45.45) 83(52.20)  
 III 12(12.12) 32(20.13)